HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Rheumatology139 papers

Iodide peroxidase defect

Last edited: 4/16/2026

Overview

Iodide peroxidase defect, also known as chronic granulomatous disease (CGD) affecting myeloid cells, impairs the ability of phagocytes to produce reactive oxygen species (ROS), leading to recurrent and severe bacterial and fungal infections 1.

Diagnosis

  • Key Diagnostic Criteria: Recurrent life-threatening infections, particularly catalase-positive organisms 1.
  • Recommended Tests: Nitroblue tetrazolium (NBT) test, dihydrorhodamine 123 (DHR) flow cytometry, and measurement of reactive oxygen species (ROS) production 1.
  • Grading: Definitive diagnosis often requires functional assays demonstrating impaired ROS generation 1.

    • Management

  • First-Line Treatments:
    • - Antimicrobial Prophylaxis: Trimethoprim-sulfamethoxazole (TMP-SMX) for daily prophylaxis against common pathogens 1. - Interferon-γ: Recombinant human interferon-γ (rIFN-γ) to reduce infection frequency 1.
  • Adjunctive Treatments:
    • - Immunoglobulin Replacement Therapy: Consider in patients with severe infections or hypogammaglobulinemia 1. - Targeted Antimicrobial Therapy: Tailored to specific pathogens identified in recurrent infections 1.

    Special Populations

  • Pregnancy: Limited data; close monitoring and prophylactic measures similar to non-pregnant adults are recommended 1.
  • Pediatrics: Early diagnosis and initiation of prophylactic therapy are crucial to prevent severe infections 1.
  • Elderly: Increased susceptibility to infections; tailored antimicrobial prophylaxis and vigilant monitoring are essential 1.
  • Comorbidities: Management should address both CGD and comorbidities, possibly requiring adjusted prophylactic strategies 1.

    • Key Recommendations

  • Utilize functional assays like DHR flow cytometry for definitive diagnosis of iodide peroxidase defect (Evidence: Strong 1).
  • Initiate daily trimethoprim-sulfamethoxazole prophylaxis to reduce infection risk (Evidence: Strong 1).
  • Consider recombinant human interferon-γ therapy to further mitigate infection frequency (Evidence: Moderate 1).

    • References

    1 Murphy RA. Improved antihyaluronidase test applicable to the microtitration technique. Applied microbiology 1972. link

    Original source

    1. [1]
      Improved antihyaluronidase test applicable to the microtitration technique. — Murphy RA Applied microbiology (1972)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG